Two variables –lessen curiosity rates as well as small valuation of numerous biotech stocks — are very likely to end in many biotech businesses remaining acquired in 2024. Decreased desire prices will cause quite a few drug maker stocks getting obtained for the reason that cheaper borrowing prices could make it cheaper for corporations to borro